Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (131-140 of 201) with videos related to

Pageof 21
Sort By:
Neuro-Oncology Advances|May 22, 2023
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2Justin T Jordan, Christina C Orr, Raquel D Thalheimer, et al.
Clinical Trials (London, England)|June 3, 2023
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trialsAshley Cannon, Kavita Y Sarin, Andrea K Petersen, et al.
Neurology|July 7, 2021
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based AssessmentShivani Ahlawat, K Ina Ly, Laura M Fayad, et al.
Theranostics|February 16, 2026
A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activationZhenzhen Yin, Simeng Lu, Limeng Wu, et al.
Neurology|July 11, 2018
Cutaneous neurofibromas: Current clinical and pathologic issuesNicolas Ortonne, Pierre Wolkenstein, Jaishri O Blakeley, et al.
Medicine|February 1, 2018
Pain correlates with germline mutation in schwannomatosisJustin T Jordan, Miriam J Smith, James A Walker, et al.
Journal of Pediatric Orthopedics|August 28, 2020
Are Some Randomized Clinical Trials Impossible?Jonathan J Rios, B Stephens Richards, David A Stevenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Neurosurgery|March 1, 2022
Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical TrialAnurag Saraf, Luke R G Pike, Kevin H Franck, et al.
Neuro-Oncology|April 3, 2023
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannomaScott R Plotkin, Jeffrey Allen, Girish Dhall, et al.
Pageof 21

Showing results (131-140 of 201) with videos related to

Sort By:
Pageof 21
Neuro-Oncology Advances|May 22, 2023
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2Justin T Jordan, Christina C Orr, Raquel D Thalheimer, et al.
Clinical Trials (London, England)|June 3, 2023
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trialsAshley Cannon, Kavita Y Sarin, Andrea K Petersen, et al.
Neurology|July 7, 2021
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based AssessmentShivani Ahlawat, K Ina Ly, Laura M Fayad, et al.
Theranostics|February 16, 2026
A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activationZhenzhen Yin, Simeng Lu, Limeng Wu, et al.
Neurology|July 11, 2018
Cutaneous neurofibromas: Current clinical and pathologic issuesNicolas Ortonne, Pierre Wolkenstein, Jaishri O Blakeley, et al.
Medicine|February 1, 2018
Pain correlates with germline mutation in schwannomatosisJustin T Jordan, Miriam J Smith, James A Walker, et al.
Journal of Pediatric Orthopedics|August 28, 2020
Are Some Randomized Clinical Trials Impossible?Jonathan J Rios, B Stephens Richards, David A Stevenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Neurosurgery|March 1, 2022
Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical TrialAnurag Saraf, Luke R G Pike, Kevin H Franck, et al.
Neuro-Oncology|April 3, 2023
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannomaScott R Plotkin, Jeffrey Allen, Girish Dhall, et al.
Pageof 21